Grant & Eisenhofer Appointed Lead Counsel in Lawsuit Alleging CIBC and RBC Manipulated Quantum BioPharma Stock

Pune, India, October 8th, 2026, FinanceWire

Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court for the Southern District of New York has agreed to consolidate both the Company’s direct action and a class action led by an individual investor alleging market manipulation. In addition, the court appointed experienced law firm Grant & Eisenhofer P.A. (“Grant & Eisenhofer”) as lead counsel in the class action.  According to Grant & Eisenhofer, the firm has recovered over USD $30 Billion dollars for its clients to date in some of the most complex, often precedent-setting cases, in fights against the world’s largest and richest opponents.  

The Quantum Biopharma lawsuit alleged that between January 1, 2020, and August 15, 2024, the Defendants and/or their customers used “spoofing” techniques to manipulate the share price of Quantum Biopharma shares. The class action lawsuit filed December 11, 2025, alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.  

A link to the Court’s ruling can be found here: Opinion and Order 25-cv-10565 (ER)

For more information, users can visit: www.quantumbiopharma.com under the page Quantum vs Banks. 

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc. ("Unbuzzd") (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from Unbuzzd until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information, users can visit www.quantumbiopharma.com.

The following companies are not related to Quantum BioPharma or the litigation described above, and they are included for general market awareness only.. Tempus (NASDAQ: TEM) recently announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The collaboration builds on joint efforts initiated last year and will support preparations for the potential commercialization of intismeran autogene. Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, recently announced it will report its financial results for the third quarter of 2026 on Monday, November 2, 2026, before the opening of the U.S. financial markets. Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, recently announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV). In addition, 48-week data from the Phase 2b portion of AZURE-1 demonstrated deepening viral suppression, with a greater proportion of patients achieving HDV RNA below the lower limit of quantification (LLOQ, <10 IU/mL) and target not detected (TND), and increased rates of alanine aminotransferase (ALT) normalization. AZURE-1 is one of two pivotal Phase 3 studies intended to form the basis of Mirum's U.S. registration package for brelovitug.

Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable securities laws, including the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical fact and may include statements regarding the Company’s litigation against the defendants, the effect of the Court’s decision to consolidate the related actions, the conduct and timing of the consolidated litigation, the Company’s ability to pursue its claims, the potential recovery of damages or other relief, and the Company’s expectations regarding the ultimate outcome of the litigation. Forward-looking statements are often identified by words such as “may,” “will,” “should,” “expect,” “anticipate,” “believe,” “intend,” “estimate,” “potential,” “continue,” “could” and similar expressions, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on management’s current expectations, assumptions and beliefs and are subject to significant risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the inherent uncertainty, cost and duration of litigation; the possibility of appeals, procedural rulings, delays, settlement discussions or other developments; the Company’s ability to prove its allegations and establish liability, causation and damages; the defendants’ defenses and counterarguments; the amount, if any, of damages or other relief that may ultimately be awarded or recovered; the collectability of any judgment or settlement; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Court’s consolidation of the related actions and appointment of lead counsel are procedural developments and do not constitute a determination on the merits of the Company’s claims or any finding of liability or damages. There can be no assurance that the litigation will result in a favorable judgment, settlement, recovery of the amount claimed, or any recovery at all.

Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date hereof and are expressly qualified in their entirety by this cautionary statement. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise.

Contacts: 

Investor Relations

Robert Guzman, Investor Relations 

Email: Rob@QuantumBioPharma.com  

Telephone: (833) 304-0323

General Inquiries: info@QuantumBioPharma.com

Disclaimer: This is a paid advertisement. USA Stock Report and its affiliates, including Akchirpy Media LLP, have been compensated a total of Five thousand USD by FinnCom, Inc. for the distribution of this press release regarding Quantum BioPharma Ltd. (NASDAQ: QNTM). This compensation covers the period of 6th October to 8th October, 2026. This disclosure is made in accordance with Section 17(b) of the Securities Act of 1933. The content above is an official press release issued by Quantum BioPharma Ltd. It is republished in full and without changes. We have not independently verified the information it contains. Statements about the litigation reflect the company’s allegations only. No court has made any finding of liability or damages. There is no assurance of any recovery or favorable outcome. USA Stock Report, its owners, and its employees do not hold any position in QNTM. We do not intend to buy or sell QNTM shares during this campaign. Nothing on this page is investment advice or a recommendation to buy or sell any security. We are not registered investment advisers or broker-dealers. Investing in small-cap and microcap stocks carries a high degree of risk, including the loss of your entire investment. Always do your own research and consult a licensed financial professional before making any investment decision. The press release contains forward-looking statements. Actual results may differ materially. Please read the company’s full cautionary statement and its filings at www.sec.gov. Tempus, Axsome Therapeutics, and Mirum Pharmaceuticals, as well as Moderna and Merck, are not affiliated with Quantum BioPharma Ltd and are included in this article for general market awareness only. They did not pay for or review this content. USA Stock Report, its owners, and its employees hold no positions in TEM, AXSM, MIRM, MRNA, or MRK.

Source: https://finance.yahoo.com/markets/stocks/articles/world-renowned-law-firm-grant-120000481.html

Contact